Ozagrel HCl | CAS# 74003-18-2 | Thromboxane A2 synthase inhibitor

MedKoo Cat#: 574837 | Name: Ozagrel HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ozagrel HCl is a selective thromboxane A2 synthase inhibitor which has been shown to alleviate liver injury induced by acetaminophen overdose.

Chemical Structure

Ozagrel HCl

CAS#74003-18-2 (HCl)

Theoretical Analysis

MedKoo Cat#: 574837

Name: Ozagrel HCl

CAS#: 74003-18-2 (HCl)

Chemical Formula: C13H13ClN2O2

Exact Mass: 0.0000

Molecular Weight: 264.71

Elemental Analysis: C, 58.99; H, 4.95; Cl, 13.39; N, 10.58; O, 12.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

189224-26-8 (sodium) 82571-53-7 (free base) 74003-18-2 (HCl)

Synonym

Ozagrel hydrochloride, Ozagrel HCl; OKY 046; Xanbon

IUPAC/Chemical Name

(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]-2-propenoic Acid Hydrochloride

InChi Key

CWKFWBJJNNPGAM-IPZCTEOASA-N

InChi Code

InChI=1S/C13H12N2O2.ClH/c16-13(17)6-5-11-1-3-12(4-2-11)9-15-8-7-14-10-15;/h1-8,10H,9H2,(H,16,17);1H/b6-5+;

SMILES Code

O=C(O)/C=C/C1=CC=C(CN2C=CN=C2)C=C1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 264.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Park SI, Park SK, Jang KS, Han YM, Kim CH, Oh SJ. Preischemic neuroprotective effect of minocycline and sodium ozagrel on transient cerebral ischemic rat model. Brain Res. 2015 Mar 2;1599:85-92. doi: 10.1016/j.brainres.2014.12.051. Epub 2014 Dec 31. PubMed PMID: 25555371. 2: Wada T, Yasunaga H, Horiguchi H, Fushimi K, Matsubara T, Nakajima S, Yahagi N. Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis. J Stroke Cerebrovasc Dis. 2016 Aug 23. pii: S1052-3057(16)30261-0. doi: 10.1016/j.jstrokecerebrovasdis.2016.07.044. [Epub ahead of print] PubMed PMID: 27567296. 3: Tange M, Yoshida M, Hazekawa M, Haraguchi T, Nakai Y, Uchida T. Prediction of compatibility between ozagrel sodium preparation for injection and calcium on the basis of the solubility product. Chem Pharm Bull (Tokyo). 2013;61(5):567-71. Epub 2013 Mar 1. PubMed PMID: 23449252. 4: Zhang J, Yang J, Chang X, Zhang C, Zhou H, Liu M. Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials. Neurol Res. 2012 May;34(4):346-53. doi: 10.1179/1743132812Y.0000000022. PubMed PMID: 22643078. 5: Yang B, Shi J, Chen X, Ma B, Sun H. Efficacy and safety of therapies for acute ischemic stroke in China: a network meta-analysis of 13289 patients from 145 randomized controlled trials. PLoS One. 2014 Feb 13;9(2):e88440. doi: 10.1371/journal.pone.0088440. eCollection 2014. PubMed PMID: 24551100; PubMed Central PMCID: PMC3923787. 6: Xu SH, Yin MS, Liu B, Chen ML, He GW, Zhou PP, Cui YJ, Yang D, Wu YL. Tetramethylpyrazine-2'-O-sodium ferulate attenuates blood-brain barrier disruption and brain oedema after cerebral ischemia/reperfusion. Hum Exp Toxicol. 2016 Jul 6. pii: 0960327116657401. [Epub ahead of print] PubMed PMID: 27387348. 7: Wu H, Yu W, Huang L, Wang J, Tang X, Yang W, Liu Y, Yu H, Zhu D. Effect of sodium ozagrel on the activity of rat CYP2D6. Eur J Pharmacol. 2007 Nov 14;573(1-3):55-9. Epub 2007 Jul 4. PubMed PMID: 17651725. 8: Shinohara Y, Inoue S. Cost-effectiveness analysis of the neuroprotective agent edaravone for noncardioembolic cerebral infarction. J Stroke Cerebrovasc Dis. 2013 Jul;22(5):668-74. doi: 10.1016/j.jstrokecerebrovasdis.2012.04.002. Epub 2012 May 22. PubMed PMID: 22622391. 9: Yao HX, Huang L, Wu CM, Lin LE, Huang ZQ, Wu JF, Wang SW, Chen WT, Tang RM. [Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009 Oct;17(5):1360-2. Chinese. PubMed PMID: 19840484. 10: Shinohara Y, Saito I, Kobayashi S, Uchiyama S. Edaravone (radical scavenger) versus sodium ozagrel (antiplatelet agent) in acute noncardioembolic ischemic stroke (EDO trial). Cerebrovasc Dis. 2009;27(5):485-92. doi: 10.1159/000210190. Epub 2009 Mar 26. PubMed PMID: 19321945.